AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Insider Transactions Reported | Axsome Therapeutics(AXSM)saw insider trading activity on 8/26/2025
ByAinvest
Tuesday, Aug 26, 2025 10:00 pm ET1min read
Axsome Therapeutics(AXSM) saw insider trading activity on 8/26/2025, there were 2 insider trades during the day.
【History Insider Transaction】
| Declare date | Position | Name | Buy/Sell | Quantity | Price per share/USD | Total Amount/USD |
|---|---|---|---|---|---|---|
| 8/26/2025 | -- | JEFFS ROGER | Sell | 20000 | 120.03 | 2400.6k |
| 8/26/2025 | -- | JEFFS ROGER | Sell | 16694 | 120.08 | 2004.62k |
| 6/23/2025 | General Counsel | Murdock Hunter R. | Sell | 7500 | 102.47 | 768.53k |
| 6/23/2025 | General Counsel | Murdock Hunter R. | Sell | 6014 | 100.12 | 602.12k |
| 6/23/2025 | General Counsel | Murdock Hunter R. | Buy | 13514 | 29.91 | 404.2k |
| 6/18/2025 | General Counsel | Murdock Hunter R. | Buy | 22500 | 29.91 | 672.98k |
| 6/18/2025 | General Counsel | Murdock Hunter R. | Sell | 7500 | 100.90 | 756.75k |
| 6/18/2025 | General Counsel | Murdock Hunter R. | Sell | 7500 | 102.42 | 768.15k |
| 6/18/2025 | General Counsel | Murdock Hunter R. | Sell | 7500 | 100.26 | 751.95k |
| 6/10/2025 | Chief Operating Officer | Jacobson Mark L. | Buy | 25000 | 8.02 | 200.5k |
[Company Profile]
Axsome Therapeutics, Inc. was incorporated in January 2012.The company is a clinical stage biopharmaceutical company developing novel therapies for the management of pain and other central nervous system, or CNS, disorders. By focusing on this therapeutic area, They are addressing significant and growing markets where current treatment options are limited or inadequate. They aim to become a fully integrated biopharmaceutical company that develops and commercializes differentiated therapies that expand the treatment options available to caregivers and improve the lives of patients living with pain and other CNS disorders.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet